<?xml version='1.0' encoding='UTF-8'?>
<rss xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" version="2.0"><channel><title>Ophthalmology</title><link>https://nrouizem.github.io/test/ophthalmology_feed.xml</link><description>Daily curated &amp; summarized biopharma news.</description><atom:link href="https://nrouizem.github.io/test/ophthalmology_feed.xml" rel="self"/><docs>http://www.rssboard.org/rss-specification</docs><generator>python-feedgen</generator><language>en</language><lastBuildDate>Mon, 17 Mar 2025 01:20:31 +0000</lastBuildDate><item><title>How 3T Biosciences’ platform targets immunologically cold solid tumors</title><link>https://www.drugdiscoverytrends.com/3t-biosciences-targeted-strategy-for-mss-colorectal-cancer/</link><description>3T Biosciences is addressing the therapeutic challenge of immunotherapy resistance in solid tumors, particularly in microsatellite stable colorectal cancer (MSS CRC), where over 90% of cases do not respond to existing checkpoint inhibitors. Their innovative platform aims to enhance treatment effectiveness by targeting immunologically cold solid tumors and improving patient outcomes in oncology.</description><pubDate>Sat, 01 Feb 2025 05:12:51 +0000</pubDate></item><item><title>How Capsida’s unconventional funding strategy and capsid technology promise to reshape CNS treatments</title><link>https://www.drugdiscoverytrends.com/how-capsidas-unconventional-funding-strategy-and-capsid-technology-promise-to-reshape-cns-treatments/</link><description>Capsida Biotherapeutics has announced that AbbVie will exercise its option on their first neurodegenerative disease program, resulting in a $40 million license payment for the startup. This partnership highlights Capsida's successful unconventional funding strategy, leveraging collaborations with Big Pharma to advance its innovative capsid technology for CNS treatments.</description><pubDate>Sat, 01 Feb 2025 21:05:12 +0000</pubDate></item><item><title>The FDA Fast-Tracked GNSC-001 gene therapy targets osteoarthritis at its root</title><link>https://www.drugdiscoverytrends.com/the-fda-fast-tracked-gnsc-001-gene-therapy-targets-osteoarthritis-at-its-root/</link><description>The FDA has fast-tracked GNSC-001, a groundbreaking gene therapy targeting the root causes of osteoarthritis, a degenerative joint disease affecting over 30 million Americans and costing the healthcare system significantly. This innovative treatment aims to address one of modern medicine's largest unmet needs in managing OA effectively.</description><pubDate>Tue, 04 Feb 2025 19:16:27 +0000</pubDate></item><item><title>JAMA: Potential rare vision complications linked to blockbuster GLP-1s</title><link>https://www.drugdiscoverytrends.com/jama-potential-rare-vision-complications-linked-to-blockbuster-glp-1s/</link><description>A new JAMA Ophthalmology case series highlights rare but serious vision issues in patients using the diabetes treatments semaglutide and tirzepatide, with nine individuals reporting sudden vision changes. This finding raises concerns about the safety profile of these popular glucagon-like peptide-1 receptor agonists.</description><pubDate>Tue, 11 Feb 2025 17:14:58 +0000</pubDate></item><item><title>Rosnilimab phase 2b trial shows promise in treating RA</title><link>https://www.drugdiscoverytrends.com/rosnilimab-phase-2b-trial-shows-promise-in-treating-ra/</link><description>A phase 2b trial of rosnilimab shows promise in treating rheumatoid arthritis (RA) by targeting the PD-1 pathway to reset the immune system, potentially offering a new approach for patients who have not achieved long-term remission with existing therapies. This novel treatment could address the unmet needs of those cycling through traditional options like methotrexate and biologics.</description><pubDate>Wed, 19 Feb 2025 14:07:47 +0000</pubDate></item><item><title>Finding Patients, Closing Treatment Gaps, and Building Better Messaging through AI and Real-World Data</title><link>https://www.fiercebiotech.com/premium/webinar/1368842</link><description>OM1's upcoming webinar, featuring experts Joseph Zabinski and Kathryn Starzyk, explores how AI-driven digital phenotyping and real-world data can help pharmaceutical teams identify underserved patient populations and align therapies with unmet clinical needs. The session will demonstrate strategies to bridge treatment gaps, refine market messaging, and ensure therapies reach overlooked communities through advanced analytics.</description><pubDate>Thu, 06 Mar 2025 20:09:20 +0000</pubDate></item><item><title>J&amp;J Axes Late-Stage Depression Trial After Underwhelming Efficacy</title><link>https://www.biospace.com/drug-development/j-j-axes-late-stage-depression-trial-after-underwhelming-efficacy</link><description>Despite aticaprant's Phase III setback, analysts say J&amp;J's neuroscience strategy remains intact, bolstered by its recent $14.6 billion acquisition of Intra-Cellular Therapeutics. The company’s confidence is further reinforced by the continued success of Spravato, its treatment for resistant depression, positioning it to maintain momentum in the sector.</description><pubDate>Fri, 07 Mar 2025 13:46:12 +0000</pubDate></item><item><title>At $300M Kardigan startup, former MyoKardia team unveils its first drug, and it comes from Ionis</title><link>https://endpts.com/at-300m-kardigan-startup-former-myokardia-team-unveils-its-first-drug-and-it-comes-from-ionis/</link><description>Former MyoKardia executives launched a heart health biotech startup with $300 million in funding, leveraging undisclosed partnerships to secure in-licensed clinical-stage assets for cardiac therapies. The stealth-mode company remains tight-lipped about specific deals but signals a focus on advancing innovative treatments, attracting attention for its seasoned leadership and strategic collaborations.</description><pubDate>Fri, 07 Mar 2025 16:16:52 +0000</pubDate></item><item><title>J&amp;J scraps depression testing for potential blockbuster drug</title><link>https://www.biopharmadive.com/news/johnson-depression-studies-discontinue-aticaprant-neumora/741922/</link><description>A recent decision has dealt a "big blow" to a promising class of brain therapies, including Johnson &amp; Johnson’s experimental drug aticaprant and Neumora Therapeutics’ candidate, casting uncertainty over their development. While the article highlights setbacks for these specific treatments, it does not mention any new business deals, partnerships, or acquisitions related to the companies involved.</description><pubDate>Fri, 07 Mar 2025 17:08:00 +0000</pubDate></item><item><title>Multi-Modality Testing of EGFR</title><link>https://www.fiercebiotech.com/resource/multi-modality-testing-egfr</link><description>Neogenomics highlights its new white paper advocating a multi-modality testing approach to improve clinical trials, offering deeper insights into patient responses and treatment effectiveness. The sponsored resource, available for download, underscores how integrating diverse testing methods can advance oncology research and therapeutic outcomes.</description><pubDate>Fri, 07 Mar 2025 18:04:58 +0000</pubDate></item><item><title>Bayer eyes capital raise as it grapples with Monsanto cases</title><link>https://endpts.com/bayer-eyes-capital-raise-as-it-grapples-with-monsanto-cases/</link><description>Bayer seeks shareholder approval to potentially raise €35 billion through an equity offering, aiming to address mounting legal costs tied to ongoing Monsanto litigation. The proposed capital authorization would provide flexibility to swiftly secure funds as the company navigates lawsuits over Monsanto's Roundup weedkiller.</description><pubDate>Fri, 07 Mar 2025 19:41:18 +0000</pubDate></item><item><title>FDA approves Neurotech therapy for rare eye disease</title><link>https://endpts.com/fda-approves-neurotech-therapy-for-rare-eye-disease/</link><description>The FDA approved Neurotech Pharmaceuticals’ first-of-its-kind cell therapy for macular telangiectasia type 2, a rare eye disease causing progressive central vision loss, marking a major advancement for patients with no prior treatment options. The therapy, which implants cells to repair retinal damage, could transform care for the condition, though the article does not mention specific business deals or partnerships related to its development.</description><pubDate>Fri, 07 Mar 2025 19:57:13 +0000</pubDate></item><item><title>Novo Nordisk’s CagriSema shows 15.7% weight loss in second pivotal trial</title><link>https://endpts.com/novo-nordisks-cagrisema-shows-15-7-weight-loss-in-second-pivotal-trial/</link><description>Novo Nordisk announced Monday that its drug CagriSema achieved 15.7% weight loss in patients with obesity and type 2 diabetes after over a year of use, marking a potential advancement in dual-treatment therapies. The result underscores the drug’s efficacy in addressing these interconnected conditions, positioning it as a promising contender in the competitive metabolic health market.</description><pubDate>Mon, 10 Mar 2025 12:21:18 +0000</pubDate></item><item><title>J&amp;J’s Oral IL-23R Blocker Sets New Standard in Plaque Psoriasis, Beating BMS’ Sotyktu</title><link>https://www.biospace.com/drug-development/j-js-oral-il-23r-blocker-sets-new-standard-in-plaque-psoriasis-beating-bmss-sotyktu</link><description>New late-stage trial data reveals Johnson &amp; Johnson’s psoriasis drug icotrokinra outperformed Bristol Myers Squibb’s Sotyktu in clearing skin and reducing symptom severity for patients with plaque psoriasis. The findings could intensify competition in the dermatology treatment market, positioning J&amp;J’s therapy as a potential challenger in this therapeutic area.</description><pubDate>Mon, 10 Mar 2025 14:03:00 +0000</pubDate></item><item><title>BMS’ Sotyktu Notches Phase III Win in Psoriatic Arthritis</title><link>https://www.biospace.com/drug-development/bms-sotyktu-notches-phase-iii-win-in-psoriatic-arthritis</link><description>In the plaque psoriasis market, Sotyktu is locked in a competitive battle with Amgen’s Otezla while bracing for new rivalry from Alumis’ investigational TYK2 inhibitor. The intensifying competition underscores the dynamic landscape of psoriasis treatments as emerging therapies threaten to disrupt established players.</description><pubDate>Mon, 10 Mar 2025 14:07:24 +0000</pubDate></item><item><title>Novo Dips After CagriSema’s Latest Lower-Than-Expected Weight Loss Readout</title><link>https://www.biospace.com/drug-development/novo-dips-after-cagrisemas-latest-lower-than-expected-weight-loss-readout</link><description>New clinical trial results revealed CagriSema, a weight-loss drug from Novo, achieved 15.7% weight reduction in diabetic patients over 68 weeks but delivered a disappointing 22.7% in non-diabetic patients by December 2024, falling short of the company’s projected 25% efficacy. The underwhelming performance in non-diabetic trials raises questions about the drug’s competitive edge in the crowded obesity treatment market.</description><pubDate>Mon, 10 Mar 2025 14:14:35 +0000</pubDate></item><item><title>Mineralys shares climb on study data for blood pressure drug</title><link>https://www.biopharmadive.com/news/mineralys-lorundrostat-hypertension-study-results/742000/</link><description>New studies on Mineralys' hypertension treatment have validated the drug as a promising near-commercial product, with analysts hailing it as a "derisked, almost-commercial stage cardiometabolic asset." While no specific deals or partnerships were mentioned, the data bolsters the therapy’s market potential and positions it for future commercial opportunities.</description><pubDate>Mon, 10 Mar 2025 15:30:00 +0000</pubDate></item><item><title>Trevi Therapeutics stock soars on Phase 2a chronic cough data</title><link>https://endpts.com/trevi-therapeutics-stock-soars-on-phase-2a-chronic-cough-data/</link><description>Trevi Therapeutics' chronic cough drug demonstrated a 57% reduction in 24-hour cough frequency versus placebo in a Phase 2a trial, outperforming investor expectations and sparking a 40% surge in its stock ($TRVI) at market open. The breakthrough underscores the treatment’s potential and has ignited optimism among investors about the company’s clinical and commercial prospects.</description><pubDate>Mon, 10 Mar 2025 15:51:40 +0000</pubDate></item><item><title>J&amp;J, Protagonist outline first IBD win for potential immunological blockbuster</title><link>https://endpts.com/jj-protagonist-outline-first-ibd-win-for-potential-immunological-blockbuster/</link><description>Johnson &amp; Johnson and Protagonist Therapeutics have partnered to develop an oral IL-23 drug, aiming to create a breakthrough immunology treatment. The companies announced progress toward this goal on Monday, signaling potential advancements in bringing the blockbuster drug candidate closer to market.</description><pubDate>Mon, 10 Mar 2025 16:04:34 +0000</pubDate></item><item><title>#AAD25 roundup: Data from Amgen, Bristol Myers, J&amp;J, Alumis and more</title><link>https://endpts.com/aad25-roundup-data-from-amgen-bristol-myers-jj-alumis-and-more/</link><description>At the American Academy of Dermatology annual meeting, key players like Amgen, Bristol Myers Squibb, Alumis, and Kyowa Kirin spotlighted updates on their dermatology drug pipelines, though no mergers or acquisitions were highlighted. The event emphasized breakthroughs in treatments for conditions like psoriasis and eczema, showcasing the industry’s focus on advancing innovative therapies for skin diseases.</description><pubDate>Mon, 10 Mar 2025 16:37:26 +0000</pubDate></item><item><title>Deep Dive: Cardiovascular Disease Back in the Spotlight</title><link>https://www.biospace.com/drug-development/deep-dive-cardiovascular-disease-back-in-the-spotlight</link><description>BioSpace highlights the rapid evolution of emerging therapeutic modalities, from gene editing to cell therapies, as biotech and pharma companies race to innovate in a competitive market. The article underscores the intensifying battles for dominance in this space, with advancements poised to reshape treatment paradigms and spur significant industry growth.</description><pubDate>Mon, 10 Mar 2025 16:40:00 +0000</pubDate></item><item><title>Beam shares promising first clinical data on gene editing treatment</title><link>https://endpts.com/beam-shares-promising-first-clinical-data-on-gene-editing-treatment/</link><description>Beam Therapeutics' experimental gene-editing therapy demonstrated promising results in a small trial, reducing mutant proteins linked to lung-damaging alpha-1 antitrypsin deficiency and boosting corrected protein levels in nine participants. The early data underscores the treatment's potential as a one-time fix for the genetic disorder, though the article does not mention any business deals, partnerships, or mergers.</description><pubDate>Mon, 10 Mar 2025 16:42:30 +0000</pubDate></item><item><title>Novo’s Wegovy successor disappoints in second large trial</title><link>https://www.biopharmadive.com/news/novo-nordisk-cagrisema-study-results-diabetes-weight-loss/742008/</link><description>A recent study found that CagriSema, a weight-loss therapy for individuals with obesity and diabetes, demonstrated effectiveness in aiding weight loss but fell short of outperforming Eli Lilly’s rival drug Zepbound. While the results highlight CagriSema’s potential, they solidify Zepbound’s competitive edge in the burgeoning metabolic treatment market.</description><pubDate>Mon, 10 Mar 2025 17:17:00 +0000</pubDate></item><item><title>Beam base editing therapy gets ‘proof of concept’ in rare lung disease</title><link>https://www.biopharmadive.com/news/beam-aatd-base-editing-initial-data-results-302/742015/</link><description>Beam Therapeutics' shares dropped sharply despite promising early study results showing its gene-editing technology could address the genetic cause of alpha-1 antitrypsin deficiency. The stock decline highlights investor concerns even as the company advances its innovative treatment potential.</description><pubDate>Mon, 10 Mar 2025 17:25:00 +0000</pubDate></item><item><title>BioNTech's shares dip after posting lukewarm revenue guidance</title><link>https://endpts.com/biontechs-shares-dip-after-posting-lukewarm-revenue-guidance/</link><description>BioNTech shares fell 2% after projecting lower 2025 revenues, citing reduced COVID-19 vaccine demand and oversupply challenges despite a solid $4.2 billion revenue in 2023. The company plans to pivot toward advancing cancer treatments and cost-cutting measures while preparing for new vaccine launches to offset declining pandemic-related sales.</description><pubDate>Mon, 10 Mar 2025 19:37:01 +0000</pubDate></item><item><title>Making Just-in-Time Oncology Trials Work: Overcoming Barriers and Unlocking Potential</title><link>https://www.fiercebiotech.com/premium/webinar/1368918</link><description>Just-in-time (JIT) oncology trials aim to accelerate research and improve patient access by activating trial sites only after identifying eligible patients, requiring strong collaboration between sponsors, sites, and IRBs to streamline processes and pre-negotiate agreements. An upcoming webinar will explore strategies like data-driven prescreening, standardized protocols, and centralized oversight to overcome operational barriers and expand the use of JIT trials in delivering faster, cost-effective cancer treatments.</description><pubDate>Mon, 10 Mar 2025 19:50:06 +0000</pubDate></item><item><title>The true cost of steroid-toxicity</title><link>https://www.drugdiscoverytrends.com/the-true-cost-of-steroid-toxicity/</link><description>Glucocorticoids, often known as steroids, remain the standard treatment for autoimmune disorders due to their effectiveness in suppressing inflammation and alleviating symptoms. However, the article highlights the hidden costs of steroid toxicity, which can lead to significant long-term health issues.</description><pubDate>Tue, 11 Mar 2025 01:33:58 +0000</pubDate></item><item><title>Bristol Myers buys out cell therapy partner 2seventy bio</title><link>https://endpts.com/bristol-myers-buys-out-cell-therapy-partner-2seventy-bio/</link><description>Bristol Myers Squibb has agreed to acquire 2seventy bio, its longtime partner in developing the CAR-T cell therapy Abecma for multiple myeloma, in a $286 million all-cash deal. The acquisition strengthens Bristol Myers' foothold in cancer therapies, building on the companies' existing collaboration aimed at advancing cutting-edge immunocellular treatments.</description><pubDate>Tue, 11 Mar 2025 08:13:39 +0000</pubDate></item><item><title>Arvinas and Pfizer’s PROTAC vepdegestrant works in subset of breast cancer patients</title><link>https://endpts.com/arvinas-and-pfizers-protac-vepdegestrant-works-in-subset-of-breast-cancer-patients/</link><description>Arvinas and Pfizer's partnered experimental breast cancer drug, vepdegestrant, failed to outperform existing therapies in the Phase 3 VERITAC-2 trial, casting doubt on its competitive potential. The results highlight challenges for the collaboration’s aim to deliver a differentiated treatment in the crowded protein degrader landscape.</description><pubDate>Tue, 11 Mar 2025 11:56:49 +0000</pubDate></item><item><title>Beam’s Gene Editor Achieves ‘First Ever’ Genetic Correction in AATD</title><link>https://www.biospace.com/drug-development/beams-gene-editor-achieves-first-ever-genetic-correction-in-aatd</link><description>William Blair analysts highlighted BEAM-302 as a breakthrough therapy, praising its superior efficacy in its sector in a recent investor note. While the report emphasized the drug's potential to redefine treatment standards, it did not mention any specific business deals, partnerships, or acquisitions related to the product.</description><pubDate>Tue, 11 Mar 2025 13:52:59 +0000</pubDate></item><item><title>Arvinas gets positive breast cancer data, but finds differentiation a hard sell</title><link>https://www.biopharmadive.com/news/arvinas-pfizer-vepdegestrant-breast-cancer-data-veritac/742135/</link><description>Arvinas and Pfizer's partnered breast cancer drug, vepdegestrant, showed promising results in a specific patient subgroup compared to fulvestrant, though it didn't meet overall trial goals. The mixed outcomes highlight the experimental therapy's potential niche benefits while underscoring the challenges of broad efficacy in cancer treatment.</description><pubDate>Tue, 11 Mar 2025 16:45:00 +0000</pubDate></item><item><title>Viking inks CordenPharma deal to boost obesity drug supply</title><link>https://www.biopharmadive.com/news/viking-cordenpharma-obesity-drug-manufacturing-deal/742139/</link><description>A biotech firm is investing $150 million in a strategic alliance to secure expanded production capacity for a high-profile weight-loss therapy, positioning itself to meet soaring demand. The partnership underscores the company’s aggressive push to capitalize on the competitive but rapidly growing market for obesity treatments.</description><pubDate>Tue, 11 Mar 2025 17:25:00 +0000</pubDate></item><item><title>Gilead, GSK-ViiV Move Ahead With Long-Acting HIV Options Following Early-Stage Readouts</title><link>https://www.biospace.com/drug-development/gilead-gsk-viiv-move-ahead-with-long-acting-hiv-options-following-early-stage-readouts</link><description>Gilead is advancing directly to Phase III studies for its once-yearly lenacapavir, while GSK and ViiV are progressing with their long-acting antivirals following promising early-stage results. Both developments signal significant strides in the treatment of viral infections.</description><pubDate>Wed, 12 Mar 2025 13:13:49 +0000</pubDate></item><item><title>Ono pays $280M to license Ionis rare disease drug</title><link>https://www.biopharmadive.com/news/ionis-ono-sapablursen-polycythemia-vera-licensing-deal/742269/</link><description>Ionis Pharmaceuticals is conducting a Phase 2 trial for its drug sapablursen, aimed at treating individuals with polycythemia vera. The trial seeks to evaluate the efficacy and safety of the treatment in this specific patient population.</description><pubDate>Wed, 12 Mar 2025 15:12:00 +0000</pubDate></item><item><title>Roche broadens obesity drug plans with $1.65B Zealand deal</title><link>https://www.biopharmadive.com/news/roche-zealand-license-obesity-drug-amylin-petrelinitide/742278/</link><description>The Swiss pharmaceutical company has secured an agreement to access an experimental amylin-targeting treatment, which it will evaluate alongside drugs obtained from Carmot. This strategic move aims to enhance its portfolio in the treatment landscape.</description><pubDate>Wed, 12 Mar 2025 16:20:00 +0000</pubDate></item><item><title>Telix’s new lead-212 generator could dispel medical isotope scalability hurdles</title><link>https://www.pharmaceutical-technology.com/news/telixs-new-lead-212-generator-could-dispel-medical-isotope-scalability-hurdles/</link><description>Lead-212-based alpha emitters show potential in cancer therapies, but challenges remain in their commercial supply. Efforts to enhance production and distribution are crucial for harnessing these promising treatments.</description><pubDate>Thu, 13 Mar 2025 11:34:09 +0000</pubDate></item><item><title>Montara Therapeutics adds $20M to seed fundraise for neurology pipeline</title><link>https://endpts.com/montara-therapeutics-adds-20m-to-seed-fundraise-for-neurology-pipeline/</link><description>Montara Therapeutics has secured $20 million in expanded seed financing to advance its preclinical CNS drug candidates, aiming to tackle safety concerns that have historically impeded research and development. This funding will help propel their innovative pipeline towards potential breakthroughs in central nervous system treatments.</description><pubDate>Thu, 13 Mar 2025 12:00:29 +0000</pubDate></item><item><title>Amgen's Uplizna Deepens Response Against Myasthenia Gravis at 1 Year</title><link>https://www.biospace.com/drug-development/amgens-uplizna-deepens-response-against-myasthenia-gravis-at-1-year</link><description>Amgen is set to file a regulatory submission for Uplizna, currently approved for a rare ocular autoimmune disorder, for use in myasthenia gravis in the first half of 2025, backed by strong data. Analysts are optimistic about the potential of this expansion in the drug's application.</description><pubDate>Thu, 13 Mar 2025 13:28:11 +0000</pubDate></item><item><title>EC approves Otsuka and Lundbeck’s Rxulti for schizophrenia</title><link>https://www.pharmaceutical-technology.com/news/ec-otsuka-lundbeck-rxulti/</link><description>The European Commission has granted approval to Otsuka Pharmaceutical and Lundbeck for their atypical oral antipsychotic, Rxulti (brexpiprazole), specifically for the treatment of schizophrenia. This decision marks a significant advancement in mental health treatment options for patients experiencing this condition.</description><pubDate>Fri, 14 Mar 2025 10:42:42 +0000</pubDate></item><item><title>MeiraGTx and Hologen launch AI-backed gene therapy venture</title><link>https://www.pharmaceutical-technology.com/news/meiragtx-and-hologen-launch-ai-backed-gene-therapy-venture/</link><description>MeiraGTx is set to advance its Parkinson's gene therapy into Phase III trials, backed by up to $430 million in funding from Hologen. This investment signifies a significant boost for MeiraGTx's efforts in developing innovative treatments for the disease.</description><pubDate>Fri, 14 Mar 2025 11:27:54 +0000</pubDate></item><item><title>Altimmune to put its incretin into addiction trials; Tarsus aims to raise $125M</title><link>https://endpts.com/altimmune-to-put-its-incretin-into-addiction-trials-tarsus-aims-to-raise-125m/</link><description>Altimmune announced plans to test its incretin product in addiction treatment, following a similar strategy recently adopted by Novo Nordisk. The company highlights the potential of its drug in addressing addiction issues, signaling a focus on innovative therapies in the pharmaceutical landscape.</description><pubDate>Fri, 14 Mar 2025 15:17:18 +0000</pubDate></item><item><title>RFK Jr. convened roundtable around ways to reduce stem cell regulation</title><link>https://endpts.com/rfk-jr-convened-roundtable-around-ways-to-reduce-stem-cell-regulation/</link><description>HHS Secretary Robert F. Kennedy Jr. convened a roundtable last Wednesday to address regulatory challenges in the field of regenerative medicine, focusing particularly on stem cell treatments. The meeting aimed to explore strategies to reduce obstacles that hinder the development and implementation of these therapies.</description><pubDate>Fri, 14 Mar 2025 15:36:02 +0000</pubDate></item><item><title>How biosimulation and virtual trials can bust through clinical trial roadblocks</title><link>https://www.drugdiscoverytrends.com/how-biosimulation-and-virtual-trials-can-bust-through-clinical-trial-roadblocks/</link><description>Over 300 million people globally suffer from rare diseases, with about 95% lacking FDA-approved treatments, presenting significant challenges for traditional clinical trials due to small patient populations. However, emerging biosimulation and virtual trial methods offer a promising solution to overcome these obstacles, as highlighted by Oxana Iliach, vice-chair.</description><pubDate>Fri, 14 Mar 2025 15:54:00 +0000</pubDate></item><item><title>Recipharm hits record revenue, eyes GLP-1 deals for growth</title><link>https://endpts.com/recipharm-hits-record-revenue-eyes-glp-1-deals-for-growth/</link><description>Greg Behar's strategic changes at Recipharm have resulted in record-high revenues in his first year as CEO, highlighting the company's successful adaptation to market demands. The CDMO is poised to leverage the growing GLP market to further enhance its growth prospects.</description><pubDate>Fri, 14 Mar 2025 17:07:23 +0000</pubDate></item><item><title>UK’s drugmaker rebate plan draws scrutiny from industry</title><link>https://endpts.com/uks-drugmaker-rebate-plan-draws-scrutiny-from-industry/</link><description>The UK government intends to double the amount drugmakers must repay to the National Health Service from their medicine sales, a decision that has faced significant opposition from the pharmaceutical industry. This controversial measure aims to curb NHS spending but raises concerns about its potential impact on innovation and access to new treatments.</description><pubDate>Fri, 14 Mar 2025 17:47:32 +0000</pubDate></item><item><title>Federal Circuit ruling keeps Amgen's Eylea biosimilar on the market</title><link>https://endpts.com/federal-circuit-ruling-keeps-amgens-eylea-biosimilar-on-the-market/</link><description>The US Court of Appeals for the Federal Circuit ruled against Regeneron in a significant patent infringement case concerning its eye drug Eylea and Amgen's biosimilar Pavblu. The decision marks a major win for Amgen as it continues to challenge Regeneron's market dominance in ophthalmology.</description><pubDate>Fri, 14 Mar 2025 19:05:53 +0000</pubDate></item><item><title>AbbVie builds the case for ovarian cancer drug Elahere</title><link>https://pharmaphorum.com/news/abbvie-builds-case-ovarian-cancer-drug-elahere</link><description>AbbVie is banking on new survival data to boost the market performance of its rapidly growing ovarian cancer treatment, Elahere. The company aims to leverage this data to enhance patient outcomes and strengthen its position in the oncology market.</description><pubDate>Sun, 16 Mar 2025 19:56:12 +0000</pubDate></item></channel></rss>